نتائج واعدة لحبة GLP-1 الفموية في تجربة لمرض السكري

15 يونيو، 2026

من إعداد الذكاء الاصطناعي

أظهر دواء تجريبي جديد يؤخذ عن طريق الفم يسمى إليكوغليبرون (elecoglipron) تحسناً في التحكم بمستويات السكر في الدم وساعد في فقدان الوزن لدى البالغين المصابين بداء السكري من النوع الثاني خلال تجربة سريرية من المرحلة الثانية ب. وقد تم عرض نتائج دراسة (SOLSTICE) في الجلسات العلمية للجمعية الأمريكية للسكري ونُشرت في دورية ذا لانسيت (The Lancet).

ضمت التجربة، التي ترعاها شركة أسترازينيكا، 406 بالغين من تسع دول مختلفة، حيث تلقى المشاركون جرعات متفاوتة من ناهض مستقبلات GLP-1 غير الببتيدي إليكوغليبرون أو دواء وهمي لمدة 26 أسبوعاً. ووصل ما يصل إلى 89.6 بالمئة ممن تناولوا الدواء إلى مستوى خضاب الدم السكري (HbA1c) أقل من 7 بالمئة، مقارنة بـ 24.9 بالمئة في مجموعة الدواء الوهمي. كما حقق ما يصل إلى 72.3 بالمئة فقداناً في وزن الجسم بنسبة 5 بالمئة على الأقل، مقابل 20.2 بالمئة في مجموعة الدواء الوهمي. وذكرت فانيتا أرودا، الباحثة الرئيسية في الدراسة ومديرة الأبحاث السريرية للسكري في ماس جنرال بريغهام (Mass General Brigham)، أن النتائج تسلط الضوء على إمكانات علاجات GLP-1 الفموية في تجاوز قيود الخيارات الحالية القائمة على الحقن أو الببتيدات، مشيرة إلى أن ملف سلامة الدواء يتوافق مع أدوية أخرى من نفس الفئة.

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

21 مايو، 2026 من إعداد الذكاء الاصطناعي صورة مولدة بواسطة الذكاء الاصطناعي تم التحقق من الحقائق

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

A year-long observational study in Japan suggests that people with type 2 diabetes who tend to overeat in response to tempting food cues such as sight and smell may see greater weight loss—and possibly better blood-sugar improvement—after starting GLP-1 receptor agonists, while those with primarily emotional eating patterns show less consistent links to long-term outcomes.

Trojan horse obesity drug boosts weight loss in mice

8 مايو، 2026 من إعداد الذكاء الاصطناعي

Scientists have developed a hybrid obesity treatment that uses GLP-1 and GIP signals to deliver a metabolic enhancer directly into cells. Early tests in mice showed greater weight loss and better blood sugar control than standard therapies. The approach aims to reduce side effects by limiting the drug's action to targeted areas.

صحة

Semaglutide shows strong weight loss results for adults over 65

تكنولوجيا

AI analysis of Reddit posts highlights potential underrecognized side effects linked to GLP-1 drugs

صحة

Study links PAM gene variants to weaker blood-sugar response to GLP-1 drugs such as Ozempic

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

The US Food and Drug Administration approved Foundayo, a new once-daily pill for obesity treatment, on Wednesday. Eli Lilly, the manufacturer, also produces the weight-loss injection Zepbound. The approval positions Foundayo as the second obesity pill cleared by the FDA.

Evolocumab reduces heart attack risk by 31% in high-risk diabetes patients

30 مارس، 2026 من إعداد الذكاء الاصطناعي

Researchers from Mass General Brigham found that the cholesterol drug evolocumab cuts the risk of first-time major cardiovascular events by 31% in high-risk patients with diabetes who lack diagnosed atherosclerosis. The results, from a subgroup analysis of the VESALIUS-CV trial, were presented at the American College of Cardiology's Annual Scientific Session and published in JAMA. Patients on the drug saw LDL cholesterol levels drop significantly alongside standard treatments.

Gene-editing drug slashes bad cholesterol 62 percent in trial

An experimental therapy called VERVE-102 lowered LDL cholesterol by up to 62 percent after a single dose in an early safety study. The results come from a Phase I trial involving 35 patients with high cholesterol or early cardiovascular disease. Data were published this week in the New England Journal of Medicine.

Omega-3 fish oil shows promise against non-obese type 2 diabetes

31 مايو، 2026 من إعداد الذكاء الاصطناعي

A Brazilian study found that fish oil supplements reduced insulin resistance and inflammation in rats modeling non-obese type 2 diabetes. The research highlights a potential role for omega-3 fatty acids in cases where obesity is not a factor.

14 يونيو 2026 20:36

نتائج واعدة لحبة GLP-1 الفموية في تجربة لمرض السكري

مقالات ذات صلة

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

Trojan horse obesity drug boosts weight loss in mice

Semaglutide shows strong weight loss results for adults over 65

AI analysis of Reddit posts highlights potential underrecognized side effects linked to GLP-1 drugs

Study links PAM gene variants to weaker blood-sugar response to GLP-1 drugs such as Ozempic

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Evolocumab reduces heart attack risk by 31% in high-risk diabetes patients

Gene-editing drug slashes bad cholesterol 62 percent in trial

Omega-3 fish oil shows promise against non-obese type 2 diabetes

Study: Physical activity fell after some patients with obesity started GLP-1 drugs

Study links GLP-1 drugs to lower breast cancer risk

Study finds GLP-1 hormone at very low levels in arthritic joint fluid

Study finds people who use Ozempic-like drugs for weight loss face added stigma

Study links Ozempic to lower depression and anxiety risks

Young Indians risk health with Ozempic, Mounjaro for pre-wedding weight loss

Gut reset procedure limits weight regain after stopping Ozempic

Trial finds metformin may let adults with type 1 diabetes use less insulin without improving insulin resistance

Enlicitide pill reduces LDL cholesterol by 60% in phase 3 trial

Cleveland Clinic study finds limited weight regain after stopping GLP-1 drugs

يستخدم هذا الموقع ملفات تعريف الارتباط